Jacobs Levy Equity Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Jacobs Levy Equity Management’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-62,645	Closed	-$1.13M	–	1125
2020 Q3	$1.13M	Sell	62,645 -10,927	-15%	-$226K	0.01%	639
2020 Q2	$1.87M	Buy	+73,572	New	+$1.58M	0.02%	547
2020 Q1	–	Sell	-17,829	Closed	-$393K	–	1133
2019 Q4	$393K	Sell	17,829 -14,100	-44%	-$284K	﹤0.01%	817
2019 Q3	$459K	Buy	+31,929	New	+$456K	0.01%	728
2017 Q1	–	Sell	-55,319	Closed	-$159K	–	1043
2016 Q4	$159K	Sell	55,319 -400	-0.7%	-$1.42K	﹤0.01%	854
2016 Q3	$328K	Sell	55,719 -38,700	-41%	-$136K	0.01%	790
2016 Q2	$283K	Buy	94,419 +30,473	+48%	+$125K	0.01%	896
2016 Q1	$343K	Buy	+63,946	New	+$404K	0.01%	827

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jacobs Levy Equity Management's DRNA Position: Q4 2020 in Review

Jacobs Levy Equity Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2020, closing a stake of 62,645 shares — an estimated $1.13M sold.

Jacobs Levy Equity Management first reported a position in DRNA in Q1 2016 and held it in 8 quarters. The position peaked at $1.87M in Q2 2020. 173 funds tracked by Wall St. Rank hold DRNA as of Q4 2020.

Jacobs Levy Equity Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
Jacobs Levy Equity Management sold 62,645 Dicerna Pharmaceuticals, Inc. shares in Q4 2020, an estimated $1.13M.
Jacobs Levy Equity Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2016 and held it in 8 quarters.
Jacobs Levy Equity Management's Dicerna Pharmaceuticals, Inc. position peaked at $1.87M in Q2 2020.
173 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2020.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2020, filed 16 Feb 2021.